2018
DOI: 10.1002/rmb2.12221
|View full text |Cite
|
Sign up to set email alerts
|

Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis

Abstract: BackgroundOne recent study reports cancer driver mutations in deep endometriosis, but its biological/clinical significance remains unclear. Since the natural history of endometriosis is essentially gradual progression toward fibrosis, it is thus hypothesized that the six driver genes reported to be mutated in endometriosis (the RP set) may play important roles in fibrogenesis but not necessarily malignant transformation.MethodsExtensive PubMed search to see whether RP and another set of driver genes not yet re… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
35
0
10

Year Published

2019
2019
2022
2022

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 45 publications
(47 citation statements)
references
References 408 publications
(815 reference statements)
2
35
0
10
Order By: Relevance
“…Endometriosis lesions have an altered biology. Local estrogen production (154) (186,187). These changes are increasingly viewed as a consequence of genetic or epigenetic polymorphism (154,(188)(189)(190).…”
Section: Figurementioning
confidence: 99%
“…Endometriosis lesions have an altered biology. Local estrogen production (154) (186,187). These changes are increasingly viewed as a consequence of genetic or epigenetic polymorphism (154,(188)(189)(190).…”
Section: Figurementioning
confidence: 99%
“…In fact, even for adenomyosis, there might be two or more different pathogenic origins, for example, the FAOM, or extrinsic or external adenomyosis, might originate from the invasion of neighboring DE lesions. Future phylogenic analysis based on the next-generation sequencing should be able to resolve this issue [101]. Even within the framework of the TIAR theory, endometriosis also originates from the microtraumatization, and the pathogenesis seems to be different from that of adenomyosis.…”
Section: Similarities and Difference In Pathogenesis Between Adenomyomentioning
confidence: 99%
“…The 'driver genes' like ARID1A, PIK3CA, KRAS, PPP2R1A and TP53 are reportedly present in benign, nonmalignant settings and thus the issue of oncogenicity needs to be considered in tissue context-dependent manner [165]. Guo [166] suggests that a web of gene expressions anchored by the set of driver genes, (e.g. TP53, PTEN, ARID1A, PIK3CA, KRAS and PPP2R1A, CDKN2A, NF2 and NOTCH1) are likely to be involved in inducing EMT and progressive fibrogenesis in ET lesions.…”
Section: Oncogenes and Tumor Suppressor Genesmentioning
confidence: 99%
“…TP53, PTEN, ARID1A, PIK3CA, KRAS and PPP2R1A, CDKN2A, NF2 and NOTCH1) are likely to be involved in inducing EMT and progressive fibrogenesis in ET lesions. Cyclic bleeding associated with inflammatory and oxidative stress followed by subsequent tissue repair similar to that occurring in EE may be viewed as wounds that undergo repeated tissue injury followed by repair along with recurrent estrogenic stimulation and ovulatory events which in the pelvic environment lead to smooth muscle metaplasia (SMM) and fibrogenesis associated with epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast trans-differentiation (FMT), and tumorigenesis especially in high risk patients [166][167][168][169].…”
Section: Oncogenes and Tumor Suppressor Genesmentioning
confidence: 99%